神経芽細胞腫治療薬の世界市場2019-2023

◆英語タイトル:Global Neuroblastoma Drugs Market 2019-2023
◆商品コード:IRTNTR30755
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年1月28日
◆ページ数:118
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、神経芽細胞腫治療薬の世界市場について調査・分析し、市場概要、市場環境、神経芽細胞腫治療薬市場規模、製品別(化学療法、免疫療法、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・神経芽細胞腫治療薬の世界市場概要
・神経芽細胞腫治療薬の世界市場環境
・神経芽細胞腫治療薬の世界市場動向
・神経芽細胞腫治療薬の世界市場規模
・神経芽細胞腫治療薬の世界市場:業界構造分析
・神経芽細胞腫治療薬の世界市場:製品別(化学療法、免疫療法、その他)
・神経芽細胞腫治療薬の世界市場:地域別市場規模・分析
・神経芽細胞腫治療薬の北米市場規模・予測
・神経芽細胞腫治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・神経芽細胞腫治療薬のアジア太平洋市場規模・予測
・神経芽細胞腫治療薬の主要国分析
・神経芽細胞腫治療薬の世界市場:意思決定フレームワーク
・神経芽細胞腫治療薬の世界市場:成長要因、課題
・神経芽細胞腫治療薬の世界市場:競争環境
・神経芽細胞腫治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Neuroblastoma is the most common type of childhood cancer. and its incidence is gradually increasing across the world. The exact etiological factor contributing to neuroblastoma remains undefined. However, the rising birth rate is a major contributor to the growing incidence of neuroblastoma. The incidence of neuroblastoma is increasing in developed as well as developing countries. Thus, the rising incidence of neuroblastoma is one of the driving factors for the market growth. Technavio’s analysts have predicted that the neuroblastoma drugs market will register a CAGR of over 4% by 2023.
Market Overview
Growing demand for anti-GD2 antibodies
The identification of the therapeutic targets on tumor cells or within the signaling cascade that leads to tumor growth is a promising field in cancer research. GD2 (O-acetyl-GD2 ganglioside) has been identified as a cell surface antigen that is overexpressed in neuroblastoma. These drugs do not pose any cytotoxic effects in the body. Therefore, physicians are switching toward prescribing anti-GD2 monoclonal antibodies for the treatment of neuroblastoma.
High cost of treatment
Children with neuroblastoma typically undergo many rounds of complex and intensive treatment, comprising several cycles of chemotherapy. The long duration increases the treatment costs. Drugs for the treatment of neuroblastoma, especially immunotherapy drugs, are considerably expensive. This increases the manufacturing costs of these drugs and subsequently the prices.
For the detailed list of factors that will drive and challenge the growth of the neuroblastoma drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately concentrated and with the presence of very few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Chemotherapy – Market size and forecast 2018-2023
• Immunotherapy – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Improvements in research and development for treatment of relapsed refractory neuroblastoma
• Availability of improved diagnostic modalities
• Rising number of patient support initiatives
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb
• Johnson & Johnson
• Pfizer
• Teva Pharmaceutical
• United Therapeutics
PART 14: APPENDIX
• Research methodology
• List of abbreviations

Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline molecules for neuroblastoma
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Product – Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Chemotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Chemotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 23: Immunotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Immunotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 25: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others – Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America – Year-over-year growth 2019-2023 (%)
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: Quarterly sales for UNITUXIN in $ millions
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Novel therapies under research and development for neuroblastoma
Exhibit 45: Patient support initiatives for neuroblastoma
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Bristol-Myers Squibb – Vendor overview
Exhibit 52: Bristol-Myers Squibb – Business segments
Exhibit 53: Bristol-Myers Squibb – Organizational developments
Exhibit 54: Bristol-Myers Squibb – Geographic focus
Exhibit 55: Bristol-Myers Squibb – Key offerings
Exhibit 56: Johnson & Johnson – Vendor overview
Exhibit 57: Johnson & Johnson – Business segments
Exhibit 58: Johnson & Johnson – Organizational developments
Exhibit 59: Johnson & Johnson – Geographic focus
Exhibit 60: Johnson & Johnson – Segment focus
Exhibit 61: Johnson & Johnson – Key offerings
Exhibit 62: Pfizer – Vendor overview
Exhibit 63: Pfizer – Business segments
Exhibit 64: Pfizer – Organizational developments
Exhibit 65: Pfizer – Geographic focus
Exhibit 66: Pfizer – Segment focus
Exhibit 67: Pfizer – Key offerings
Exhibit 68: Teva Pharmaceutical – Vendor overview
Exhibit 69: Teva Pharmaceutical – Business segments
Exhibit 70: Teva Pharmaceutical – Organizational developments
Exhibit 71: Teva Pharmaceutical – Geographic focus
Exhibit 72: Teva Pharmaceutical – Segment focus
Exhibit 73: Teva Pharmaceutical – Key offerings
Exhibit 74: United Therapeutics – Vendor overview
Exhibit 75: United Therapeutics – Business segments
Exhibit 76: United Therapeutics – Organizational developments
Exhibit 77: United Therapeutics – Geographic focus
Exhibit 78: United Therapeutics – Key offerings
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: List of abbreviations



【掲載企業】

Bristol-Myers Squibb、Johnson & Johnson、Pfizer、Teva Pharmaceutical、and United Therapeutics

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経芽細胞腫治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆